Canada markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.27+0.08 (+0.19%)
At close: 04:00PM EDT
41.13 -0.14 (-0.34%)
After hours: 07:59PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • S
    Scott
    The loss of their SERD (amcenenstrant) is a HUGE blow to their growth story. That was a huge pipeline drug with high expected probability of success. They have a well-covered dividend (FOR NOW). I have about 1.5% of my portfolio in Sanofi, but I wouldn't buy more at current levels until they issue a buyback / debt reduction plan to de-risk future distributions.
  • S
    Stupid Redd
    Dropping another $3 in premarket what has gone wrong
  • M
    Mr. Perfect
    Zantac ligations?No other reason,
    $Gsk,sanofi,and Pfizer but Pfizer is holding better than the rest!
  • A
    Anonymous
    5:04 am ET August 9, 2022 (Benzinga): "Sanofi Announced Monday it Would Pause the Recruitment Globally for Phase 3 Studies for MS Drug Tolebrutinib". That was yesterday's news. Any additional news?
  • D
    Deborah
    Buying cheap shares here, fickle market
  • J
    John
    A few weeks ago, Sanofi raised its full-year earnings outlook based on the 43% growth of its best-selling drug Dupixent. Sanofi expects 2022 adjusted earnings per share to grow by about 15%. Nothing has changed to justify the recent drop in share price. I bought SNY because of the relatively high dividend yield. I'm more inclined to add more shares than I am to sell now. I can bring my average price per share down and increase the dividend yield at the same time.
  • A
    Anonymous
    Calm. This is what I found about the lawsuit. It started in 2019. In July 2021, Judge Robin L. Rosenberg dismissed cases against generic drugmakers. The start date of the class action to non generic manufactures is October 10, 2022. No Zantac settlements has not been proposed. Today's $40B loss is incredible big. The worst has been in the stock price. We have not heard the defendant argument. NDMA is everywhere. It is a tough job to link. Oversold.
  • A
    Anonymous
    Broke $46. Next defense line is $43.
  • B
    BUDINE
    I couldn’t be happier with the daily emails I get from (http://growthstocks.club). They give me the best daily advice based on stock market news and help me make wiser decisions when it comes to investing. An absolute must for any investor!
  • S
    Scott
    Crazy for such a large move. No reason for this huge move. A great buying opportunity here!
  • A
    Anonymous
    A spokesperson for Sanofi said the company "remains fully confident in its defences". They added: "Given the strength of our case and the uncertainty of future proceedings no contingencies have been established."
  • A
    Anonymous
    This phase 3 failure affects Sanofi two pipelines out of 28. That is too bad. Clearly overreaction.
  • W
    WorldWasFlat
    GSK Says FDA And European Medicines Agency Have Concluded There Is No Evidence Of A Causal Association Between Ranitidine Therapy And The Development Of Cancer
  • G
    Gerry
    Does this drop have to do with the Zantac lawsuit? That's what I thought I heard this morning on CNBC. Makes sense as it is effecting GSK as well.
  • A
    Anonymous
    Tolebrutinib affects 2 out of 28 pipelines. Although bad, the today's huge selling is clearly overdone.
  • A
    Astrophysics
    The point is where FED is raising interest rates, the dividend stocks paying less than 5% to 6% will become risky and for one or the other reason will fall because also note that the FED is also playing herder of the stock markets for a slow landing and rebound in growth stocks like in June, July and today, so people will not hesitate to sell low dividend stocks and buy growth stocks aggressively.
  • A
    Anonymous
    Lawsuit & pipeline failure came at the same time. No wonder it was hit hard. An analyst downgraded, but maintained a price target of $51.